Department of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Expert Rev Gastroenterol Hepatol. 2011 Feb;5(1):59-66. doi: 10.1586/egh.10.77.
Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease associated with an increased risk of colorectal cancer (CRC). Although CRC occurs in a minority of IBD patients (1%), it carries a high mortality and accounts for 20% of IBD-related mortality. Established risk factors for the development of CRC in IBD include disease duration of 8 years or more, family history of CRC, extensive colitis and primary sclerosing cholangitis. Meticulous colonoscopy and anti-inflammatory medications can reduce the risk of developing CRC. The future of IBD surveillance involves the use of novel endoscopic techniques (chromoendoscopy, narrow-band imaging, confocal laser endomicroscopy and autofluorescence) to enhance colonoscopic accuracy, in concert with chemopreventative medications to help reduce the risk of CRC in IBD.
炎症性肠病(IBD)是一种慢性胃肠道疾病,与结直肠癌(CRC)的风险增加有关。尽管 CRC 在少数 IBD 患者(1%)中发生,但死亡率很高,占 IBD 相关死亡人数的 20%。IBD 发生 CRC 的既定危险因素包括疾病持续 8 年或更长时间、CRC 家族史、广泛性结肠炎和原发性硬化性胆管炎。仔细的结肠镜检查和抗炎药物可以降低 CRC 的发病风险。IBD 监测的未来涉及使用新型内镜技术(染色内镜、窄带成像、共聚焦激光内窥镜检查和自发荧光)来提高结肠镜检查的准确性,并结合化学预防药物来帮助降低 IBD 中 CRC 的风险。